Francisco Colman Sercovich
South Views No. 204, South Centre, Link
Sars-CoV-2, a novel pathogen, submits a stern warning, a clarion call, on the huge human costs of shortsightedness, inaction and lessons lost in the face of common predicaments at the global level. Yet, a number of key actors remain oblivious, including ethically challenged politicians seeking to elbow their way to the front of the queue at the expense of the poorest and most vulnerable nations and communities. Contrary to expectations being formed, a safe and effective vaccine for the Covid-19 strain once, if ever, attained, is the best way out but unlikely to do as a silver bullet in the midst of the complexities and unknowns at play.
As a result of the harmful impact of the pandemic and ensuing policy aftermath, the world runs the risk of squandering the gains barely made in the fight against poverty over the last few decades – a looming scenario of egregious global governance failure, in view of the eight close calls recently received (three flu epidemics or near-flu epidemics, two Sars episodes, one Mers episode, Zika & Ebola). A promptly and universally distributed vaccine promises to prevent future disease outbreaks. However, many scientific, economic and distributional hurdles stand in the way. Whilst each day counts, the survival of hundreds of millions of lives hangs in the balance as health issues and those pertaining to livelihoods, nutrition, schooling and deprivation are so closely interdependent. Can we rule out the need to resort to internationally sanctioned legal remedies as an inescapable response?
…The markets of the poorest countries, those most affected by prior pandemics thus far, are not profitable enough for wealthy countries-based multinationals to justify engaging in vaccine R&D. Beyond health-related imperatives, the large subsidies being swiftly granted by wealthy countries now in order to not just shorten schedules but also, perhaps for the most part, to ensure domestic production capacity and control of intellectual property rights, are a glaring recognition of the market failures involved and the ensuing need for public intervention — albeit often tinted by a narrow-minded nationalism. However, it is not quite clear if, in deciding to grant such subsidies, due note has been taken that the older segment of the population in rich countries, the one that bears the brunt of the pandemic in terms of mortality, is largely amongst the ones that offer the most profitable market. This circumstance, coupled by national rivalries, is leading to market segmentation and tiered pricing policies by the pharmaceutical multinationals, as confirmed by the design of actions already underway for the marketing of the future Covid-19-related vaccines and therapeutics.
